Logo image of HUMA

HUMACYTE INC (HUMA) Stock Fundamental Analysis

NASDAQ:HUMA - Nasdaq - US44486Q1031 - Common Stock - Currency: USD

3.06  -0.34 (-10%)

Premarket: 3.08 +0.02 (+0.65%)

Fundamental Rating

1

Overall HUMA gets a fundamental rating of 1 out of 10. We evaluated HUMA against 571 industry peers in the Biotechnology industry. HUMA may be in some trouble as it scores bad on both profitability and health. HUMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HUMA has reported negative net income.
HUMA had a negative operating cash flow in the past year.
In the past 5 years HUMA always reported negative net income.
HUMA had a negative operating cash flow in each of the past 5 years.
HUMA Yearly Net Income VS EBIT VS OCF VS FCFHUMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -133.20%, HUMA is doing worse than 83.04% of the companies in the same industry.
Industry RankSector Rank
ROA -133.2%
ROE N/A
ROIC N/A
ROA(3y)-33.83%
ROA(5y)-42.89%
ROE(3y)-283.23%
ROE(5y)-201.68%
ROIC(3y)N/A
ROIC(5y)N/A
HUMA Yearly ROA, ROE, ROICHUMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HUMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HUMA Yearly Profit, Operating, Gross MarginsHUMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

HUMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, HUMA has more shares outstanding
The debt/assets ratio for HUMA has been reduced compared to a year ago.
HUMA Yearly Shares OutstandingHUMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
HUMA Yearly Total Debt VS Total AssetsHUMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -10.06, we must say that HUMA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.06, HUMA is doing worse than 73.57% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.06
ROIC/WACCN/A
WACC9.18%
HUMA Yearly LT Debt VS Equity VS FCFHUMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.10 indicates that HUMA should not have too much problems paying its short term obligations.
With a Current ratio value of 1.10, HUMA is not doing good in the industry: 87.32% of the companies in the same industry are doing better.
A Quick Ratio of 1.10 indicates that HUMA should not have too much problems paying its short term obligations.
The Quick ratio of HUMA (1.10) is worse than 85.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 1.1
HUMA Yearly Current Assets VS Current LiabilitesHUMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

HUMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -54.02%.
The Revenue for HUMA has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

HUMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.08% yearly.
Based on estimates for the next years, HUMA will show a very strong growth in Revenue. The Revenue will grow by 515.22% on average per year.
EPS Next Y-24.33%
EPS Next 2Y8.39%
EPS Next 3Y21.6%
EPS Next 5Y35.08%
Revenue Next Year275.03%
Revenue Next 2Y1191.07%
Revenue Next 3Y1174.64%
Revenue Next 5Y515.22%

3.3 Evolution

HUMA Yearly Revenue VS EstimatesHUMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
HUMA Yearly EPS VS EstimatesHUMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HUMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HUMA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HUMA Price Earnings VS Forward Price EarningsHUMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HUMA Per share dataHUMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

HUMA's earnings are expected to grow with 21.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.39%
EPS Next 3Y21.6%

More info and screens

0

5. Dividend

5.1 Amount

HUMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HUMACYTE INC

NASDAQ:HUMA (3/3/2025, 8:00:02 PM)

Premarket: 3.08 +0.02 (+0.65%)

3.06

-0.34 (-10%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)03-21 2025-03-21/amc
Inst Owners35.04%
Inst Owner Change19.39%
Ins Owners10.57%
Ins Owner Change0.03%
Market Cap375.31M
Analysts81.54
Price Target13.41 (338.24%)
Short Float %26.86%
Short Ratio5.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.94%
Min EPS beat(2)-97.73%
Max EPS beat(2)-30.16%
EPS beat(4)1
Avg EPS beat(4)-37.58%
Min EPS beat(4)-97.73%
Max EPS beat(4)3.91%
EPS beat(8)4
Avg EPS beat(8)-16.29%
EPS beat(12)7
Avg EPS beat(12)34.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.08%
EPS NY rev (1m)0%
EPS NY rev (3m)3.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.34
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.74
OCFYN/A
SpS0
BVpS-0.52
TBVpS-0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -133.2%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.83%
ROA(5y)-42.89%
ROE(3y)-283.23%
ROE(5y)-201.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.01%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 1.1
Altman-Z -10.06
F-Score3
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)15%
Cap/Depr(5y)33.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32%
EPS Next Y-24.33%
EPS Next 2Y8.39%
EPS Next 3Y21.6%
EPS Next 5Y35.08%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year275.03%
Revenue Next 2Y1191.07%
Revenue Next 3Y1174.64%
Revenue Next 5Y515.22%
EBIT growth 1Y-18.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.51%
EBIT Next 3Y26.14%
EBIT Next 5Y21.82%
FCF growth 1Y-24.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.06%
OCF growth 3YN/A
OCF growth 5YN/A